TAP Blocks vs. IV Lidocaine for Kidney Transplants
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03843879 |
Recruitment Status : Unknown
Verified July 2019 by Neil Hanson, Benaroya Research Institute.
Recruitment status was: Recruiting
First Posted : February 18, 2019
Last Update Posted : July 17, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postoperative Pain | Procedure: Transversus Abdominis Plane Block Drug: Intravenous Lidocaine | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 124 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Comparison of Transversus Abdominis Plane Blocks Versus Continuous Intravenous Lidocaine for Kidney Transplant Surgery |
Actual Study Start Date : | April 1, 2019 |
Estimated Primary Completion Date : | March 1, 2021 |
Estimated Study Completion Date : | September 1, 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: TAP Block
Single-injection transversus abdominis plane block
|
Procedure: Transversus Abdominis Plane Block
Single-injection transversus abdominis plane block with 30 mL of 0.25% Bupivacaine with 1:400,000 epinephrine
Other Name: TAP Block |
Active Comparator: IV Lidocaine
Continuous intravenous lidocaine infusion
|
Drug: Intravenous Lidocaine
Continuous intravenous lidocaine infusion
Other Name: Continuous intravenous lidocaine |
- Opioid Consumption [ Time Frame: 0-24 Hours ]Total opioid utilization
- Pain Scores [ Time Frame: 0-48 Hours ]Numerical Rating Scale Pain Scores (Range: 0-10, where 0 is no pain and 10 is the worst pain)
- Opioid Consumption [ Time Frame: 24-48 Hours ]Total opioid utilization
- Opioid-Related Adverse Events [ Time Frame: 0-48 Hours ]Nausea, Vomiting, Pruritis, Respiratory Depression, Constipation
- Block/Infusion-Related Adverse Events [ Time Frame: 0-48 Hours ]Local Anesthetic Systemic Toxicity
- Opioid Usage [ Time Frame: 30 days from discharge ]Use of prescribed opioids

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Kidney transplant recipient
- >18 years old
- Consent to participate
Exclusion Criteria:
- <18 years old
- Refusal to participate
- Chronic opioid use
- Seizure disorder
- Allergy to local anesthestics
- Severe hepatic disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03843879
Contact: Neil A Hanson, MD | 206-223-6980 | neil.hanson@virginiamason.org | |
Contact: Wyndam M Strodtbeck, MD | 206-223-6980 | wyndam.strodtbeck@virginiamason.org |
United States, Washington | |
Virginia Mason Medical Center | Recruiting |
Seattle, Washington, United States, 98101 | |
Contact: Neil A Hanson, MD neil.hanson@virginiamason.org | |
Contact: Wyndam M Strodtbeck, MD wyndam.strodtbeck@virginiamason.org |
Principal Investigator: | Neil A Hanson, MD | Virginia Mason Medical Center |
Responsible Party: | Neil Hanson, Anesthesiologist, Benaroya Research Institute |
ClinicalTrials.gov Identifier: | NCT03843879 |
Other Study ID Numbers: |
IRB18-109 |
First Posted: | February 18, 2019 Key Record Dates |
Last Update Posted: | July 17, 2019 |
Last Verified: | July 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Lidocaine Anesthetics, Local Anesthetics Central Nervous System Depressants |
Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Anti-Arrhythmia Agents Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |